B-Cell Non-Hodgkin Lymphoma research hub
7 indexed studies · 5 currently recruiting
- active not recruitingPHASE1
A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
This study is testing new combinations of anti-cancer medicines for people with B-cell non-Hodgkin lymphoma that has come back or not responded to previous treatments. It aims to find safe doses and see how well these new combinations work.
United States · Belgium · Czechia - active not recruitingPHASE1, PHASE2
A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma
This study looks at new drug combinations to treat B-cell non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma. We want to see how safe and effective these new treatments are, especially when other treatments haven't worked.
United States · Belgium · Canada - recruitingPHASE1
IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas
This study is testing a new medicine, IKS03, for people with certain types of advanced B-cell non-Hodgkin lymphoma. It aims to find the safest dose and see how well it works. This is an early-stage study, meaning it's the first time it’s being given to people.
United States · Australia · Canada - recruitingPHASE1, PHASE2
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
This study is testing a new drug, surovatamig, for different types of B-cell blood cancers like leukaemia and lymphoma. Researchers want to see if it's safe and effective, either alone or with other cancer treatments.
United States · Australia · China - recruitingPHASE1, PHASE2
A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
This study is testing a new medicine, AZD4512, for people with a type of blood cancer called B-cell non-Hodgkin lymphoma that has come back or not responded to past treatments. It looks at how safe and effective the medicine is, sometimes on its own, and sometimes with other cancer drugs.
United States · Australia · China - recruitingPHASE2
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
This study is testing a new medicine called Surovatamig for adults with certain types of B-cell non-Hodgkin lymphoma that has returned or not responded to previous treatments. It aims to see how well it works and if it's safe.
United States · Australia · Brazil - recruitingPHASE2, PHASE3
A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma
This study looks for better ways to treat B-cell non-Hodgkin Lymphoma (B-NHL) in children and young people when initial treatments haven't worked or the cancer has returned. It tests new medicines to see if they are safe and effective, aiming to improve chances of recovery.
Australia · Austria · Belgium